Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11,788.00 GBX | +0.63% |
|
+1.41% | +12.61% |
08:41pm | PRESS DIGEST- Financial Times - Feb 19 | RE |
02-18 | AstraZeneca Hit With Us Class Action Lawsuit Over China Regulatory Probes - FT | RE |
Capitalization | 231B 220B 208B 183B 327B 20,036B 363B 2,469B 915B 8,364B 864B 847B 34,985B | P/E ratio 2025 * |
22.9x | P/E ratio 2026 * | 19.7x |
---|---|---|---|---|---|
Enterprise value | 250B 239B 225B 198B 354B 21,681B 393B 2,671B 990B 9,051B 935B 917B 37,858B | EV / Sales 2025 * |
4.36x | EV / Sales 2026 * | 3.98x |
Free-Float |
96.62% | Yield 2025 * |
2.16% | Yield 2026 * | 2.28% |
Last Transcript: AstraZeneca PLC
1 day | +0.63% | ||
1 week | +0.60% | ||
Current month | +3.91% | ||
1 month | +7.77% | ||
3 months | +18.14% | ||
6 months | -9.64% | ||
Current year | +12.61% |







Manager | Title | Age | Since |
---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 2012-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 51 | 2021-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 57 | 2019-12-31 |
Director | Title | Age | Since |
---|---|---|---|
Director/Board Member | 69 | 1999-04-05 | |
Pascal Soriot
BRD | Director/Board Member | 64 | 2012-09-30 |
Philip Broadley
BRD | Director/Board Member | 64 | 2017-04-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
8.29% | 59 M€ | +4.74% | - | |
5.39% | 209 M€ | +6.34% | ||
5.17% | 33 M€ | +3.72% | - | |
4.89% | 610 M€ | +11.35% |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
+0.63% | +0.60% | +16.78% | +32.18% | 229B | ||
+1.53% | -0.90% | +9.61% | +256.71% | 760B | ||
-0.74% | -0.73% | -1.00% | -5.12% | 376B | ||
+3.09% | -4.61% | -31.01% | +74.47% | 355B | ||
+1.75% | +2.30% | +10.57% | +36.26% | 340B | ||
+0.20% | +1.48% | +29.23% | -14.52% | 262B | ||
+0.34% | -3.76% | -34.82% | +9.06% | 210B | ||
+0.45% | -0.79% | +8.74% | +20.24% | 210B | ||
+0.56% | -1.30% | +3.21% | +32.63% | 156B | ||
+0.12% | +0.12% | -7.46% | -47.33% | 145B | ||
Average | +0.64% | -1.03% | +0.38% | +39.46% | 304.45B | |
Weighted average by Cap. | +0.90% | -1.12% | +1.63% | +78.83% |
2025 * | 2026 * | |
---|---|---|
Net sales | 57.27B 54.75B 51.65B 45.4B 81.27B 4,976B 90.17B 613B 227B 2,077B 215B 210B 8,689B | 60.73B 58.05B 54.77B 48.13B 86.17B 5,276B 95.6B 650B 241B 2,203B 228B 223B 9,213B |
Net income | 10B 9.56B 9.02B 7.92B 14.18B 868B 15.74B 107B 39.68B 363B 37.46B 36.72B 1,517B | 11.81B 11.29B 10.65B 9.36B 16.76B 1,026B 18.6B 126B 46.88B 428B 44.27B 43.39B 1,792B |
Net Debt | 18.94B 18.1B 17.08B 15.01B 26.87B 1,645B 29.81B 203B 75.16B 687B 70.97B 69.56B 2,873B | 11.31B 10.81B 10.2B 8.96B 16.05B 983B 17.81B 121B 44.89B 410B 42.39B 41.55B 1,716B |
Date | Price | Change | Volume |
---|---|---|---|
25-02-18 | 11,788.00 p | +0.63% | 1,256,095 |
25-02-17 | 11,714.00 p | +0.05% | 719,403 |
25-02-14 | 11,708.00 p | -2.14% | 3,001,390 |
25-02-13 | 11,964.00 p | +1.37% | 4,659,511 |
25-02-12 | 11,802.00 p | +1.53% | 4,282,148 |
Delayed Quote London S.E., February 18, 2025 at 11:35 am
More quotes
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZN Stock

MarketScreener is also available in this country: United States.
Switch edition